AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Crestor Versus Placebo in Subjects With Heart Failure
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5013
- Registration Number
- NCT00206310
- Locations
- 🇬🇧
Research Site, York, United Kingdom
A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2015-06-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 210
- Registration Number
- NCT00189514
- Locations
- 🇺🇸
Research Site, Olympia, Washington, United States
Effectiveness of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-136)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT00163384
- Locations
- 🇰🇷
Altana Pharma/Nycomed, Seoul, Korea, Republic of
Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2054
- Registration Number
- NCT00163527
- Locations
- 🇬🇧
ALTANA Pharma, Cities in the United Kindom, United Kingdom
Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 106
- Registration Number
- NCT00163488
- Locations
- 🇺🇸
Altana Pharma/Nycomed, Long Beach, California, United States
Effects of Inhaled Ciclesonide Versus Fluticasone Propionate Versus Placebo on Lower Leg Growth in Prepubertal Children With Mild Persistent Asthma (6 to 12 y) (BY9010/M1-208)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT00163371
- Locations
- 🇩🇰
Altana Pharma/Nycomed, Kolding, Denmark
Efficacy of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-137)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00163397
- Locations
- 🇨🇳
Altana Pharma/Nycomed, Taipei, Taiwan
Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (6 to 11 y) (BY9010/M1-206)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 750
- Registration Number
- NCT00163462
- Locations
- 🇿🇦
Altana Pharma/Nycomed, Wynberg, South Africa
Efficacy of Ciclesonide vs Fixed Combination of Fluticasone Propionate/Salmeterol vs Placebo in Patients With Mild Persistent Asthma (12 to 75 y) (BY9010/M1-132)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 630
- Registration Number
- NCT00163358
- Locations
- 🇪🇸
Altana Pharma/Nycomed, Valencia, Spain
Efficacy and Safety of Roflumilast Taken in the Morning or Evening in Patients With Stable Asthma (12 to 70 y) (BY217/M2-015)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-10-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 511
- Registration Number
- NCT00163475
- Locations
- 🇪🇸
ALTANA Pharma, Cities in Spain, Spain
© Copyright 2024. All Rights Reserved by MedPath